Outcome Measures of New Technologies in Uveal Melanoma: Review from the European Vision Institute Special Interest Focus Group Meeting
Beenakker, Brouwer, Chau, Coupland, Fiorentzis, Heimann, Heufelder, Joussen, Kiilgaard, Kivelä, Piperno-Neumann, Rantala, Romanowska-Dixon, Shields, Willerding, Wheeler-Schilling, Scholl, Jager, Damato and Ocular
Ophthalmic Research · 2022 · Vol. 66 · (1) · pp. 14-26 · doi: 10.1159/000524372
Read the full paper
Jan-Willem M Beenakker, Niels J Brouwer, Cindy Chau, Sarah E Coupland, Miltiadis Fiorentzis, Heinrich Heimann, Jens Heufelder, Antonia M Joussen, Jens F Kiilgaard, Tero T Kivelä, Sophie Piperno-Neumann, Elina S Rantala, Bozena Romanowska-Dixon, Carol L Shields, Gregor D Willerding, Thomas Wheeler-Schilling, Hendrik P N Scholl, Martine J Jager, Bertil E Damato and Oncology, European Ocular Oncology Group and the International Society of Ocular. Outcome Measures of New Technologies in Uveal Melanoma: Review from the European Vision Institute Special Interest Focus Group Meeting. Ophthalmic Research (2022), 66(1), 14-26. doi: 10.1159/000524372
Research Topics
Abstract
Uveal melanoma (UM) is the most common primary intraocular tumor in adults. New diagnostic procedures and basic science discoveries continue to change our patient management paradigms. A recent meeting of the European Vision Institute (EVI) special interest focus group was held on “Outcome Measures of New Technologies in Uveal Melanoma,” addressing the latest advances in UM, starting with genetic developments, then moving on to imaging and treatment of the primary tumor, as well as to investigating the most recent developments in treating metastases, and eventually taking care of the patient’s well-being. This review highlights the meeting’s presentations in the context of the published literature.